PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25297825-9 2014 Pre-treatment with DEX could up-regulate the expressions of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). Dexamethasone 19-22 BCL2 like 1 Homo sapiens 110-116 33478100-6 2021 Concurrently, DEXA up-regulates Platelet Derived Growth Factor Receptor (PDGFR) signalling, which stimulates expression of anti-apoptotic regulators BCL2L1 and MCL1, required for survival during extended mitosis. Dexamethasone 14-18 BCL2 like 1 Homo sapiens 149-155 31870784-6 2020 Upon addition of dexamethasone, GR and ASH2L recruitment is reduced, BCL-XL expression diminishes and apoptosis is induced consequently. Dexamethasone 17-30 BCL2 like 1 Homo sapiens 69-75 31669405-9 2020 After steroid treatment of damaged retinas, BCL-XL, BCL2 and BAX showed characteristic patterns depending on the use of dexamethasone or progesterone on mifepristone or light exposed retinas. Dexamethasone 120-133 BCL2 like 1 Homo sapiens 44-50 26641257-7 2016 Here, we show that Dex and anti-BCR-induced synergistic apoptosis which correlated with significant downregulation of Bcl-xL, inhibition of ERK1/2 phosphorylation and accumulation of nonphosphorylated Bim. Dexamethasone 19-22 BCL2 like 1 Homo sapiens 118-124 26641257-10 2016 In addition, overexpression of Bcl-xL prevented Dex-mediated, anti-BCR-mediated, and ABT-199-mediated apoptosis, indicating that mitochondria were involved. Dexamethasone 48-51 BCL2 like 1 Homo sapiens 31-37 19559478-2 2009 In this study, we show that apoptosis induced by dexamethasone (Dex), a synthetic glucocorticoid, was dependent on mitochondria, since overexpression of Bcl-X(L) prevented Dex-induced apoptotic changes. Dexamethasone 49-62 BCL2 like 1 Homo sapiens 153-161 24858696-15 2014 DEX stimulated upregulation of both PPARgamma and Bcl-xL at 1 dpt in normal HTFs and at 2 dpt in MMC-treated HTFs. Dexamethasone 0-3 BCL2 like 1 Homo sapiens 50-56 24858696-19 2014 We conclude that DEX reversed the MMC-inhibited HTF cell proliferation via diminishing the MMC-induced IL-8 secretion, which resulted from a late-phase upregulation of the PPARgamma and Bcl-xL. Dexamethasone 17-20 BCL2 like 1 Homo sapiens 186-192 21940343-9 2011 Anti-apoptotic genes Bcl-2 and Bcl-xL expression levels decreased after CIS treatment, but increased again after DEX addition. Dexamethasone 113-116 BCL2 like 1 Homo sapiens 31-37 20005955-0 2010 Dexamethasone protects human fibroblasts from apoptosis via an S1P3-receptor subtype dependent activation of PKB/Akt and Bcl XL. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 121-127 20005955-5 2010 Thereupon, Dex not only mediates its anti-apoptotic effect via activation of phosphoinositide 3-kinase (PI3K)/Akt signalling but also includes an involvement of the Bcl-2 family protein Bcl(XL). Dexamethasone 11-14 BCL2 like 1 Homo sapiens 186-193 20005955-6 2010 Most interestingly, the use of S1P(3)-knockout fibroblasts revealed that the S1P(3)-receptor subtype is crucial for activation of PKB/Akt as well as Bcl(XL) by Dex. Dexamethasone 160-163 BCL2 like 1 Homo sapiens 149-156 19559478-2 2009 In this study, we show that apoptosis induced by dexamethasone (Dex), a synthetic glucocorticoid, was dependent on mitochondria, since overexpression of Bcl-X(L) prevented Dex-induced apoptotic changes. Dexamethasone 172-175 BCL2 like 1 Homo sapiens 153-161 19559478-2 2009 In this study, we show that apoptosis induced by dexamethasone (Dex), a synthetic glucocorticoid, was dependent on mitochondria, since overexpression of Bcl-X(L) prevented Dex-induced apoptotic changes. Dexamethasone 64-67 BCL2 like 1 Homo sapiens 153-161 19428934-7 2009 Bak expression was increased by celecoxib and dexamethasone, while Bcl-XL level was declined only by dexamethasone. Dexamethasone 101-114 BCL2 like 1 Homo sapiens 67-73 19797168-2 2009 In rat renal IRI, a single dose of dexamethasone administered before ischemia, or at the onset of reperfusion, ameliorated biochemical and histologic acute kidney injury after 24 h. Dexamethasone upregulated Bcl-xL, downregulated ischemia-induced Bax, inhibited caspase-9 and caspase-3 activation, and reduced apoptosis and necrosis of proximal tubular cells. Dexamethasone 35-48 BCL2 like 1 Homo sapiens 208-214 19797168-2 2009 In rat renal IRI, a single dose of dexamethasone administered before ischemia, or at the onset of reperfusion, ameliorated biochemical and histologic acute kidney injury after 24 h. Dexamethasone upregulated Bcl-xL, downregulated ischemia-induced Bax, inhibited caspase-9 and caspase-3 activation, and reduced apoptosis and necrosis of proximal tubular cells. Dexamethasone 182-195 BCL2 like 1 Homo sapiens 208-214 19339209-0 2009 Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 91-97 16699951-0 2006 Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 84-90 17070682-0 2006 Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 75-81 17070682-6 2006 In FRO cells DEX stimulated in a time-dependent fashion the expression of Bcl-xL, but not that of Bcl-2, Bax and Bad. Dexamethasone 13-16 BCL2 like 1 Homo sapiens 74-80 17070682-7 2006 In addition, Bcl-xL mRNA was significantly increased in the presence of DEX, suggesting a transcriptional regulation by the steroid. Dexamethasone 72-75 BCL2 like 1 Homo sapiens 13-19 17070682-8 2006 Transfection of the cells with siRNAs against Bcl-xL inhibited both basal and DEX-stimulated Bcl-xL expression and restored apoptosis in TRAIL-stimulated cells treated with DEX. Dexamethasone 78-81 BCL2 like 1 Homo sapiens 46-52 17070682-8 2006 Transfection of the cells with siRNAs against Bcl-xL inhibited both basal and DEX-stimulated Bcl-xL expression and restored apoptosis in TRAIL-stimulated cells treated with DEX. Dexamethasone 78-81 BCL2 like 1 Homo sapiens 93-99 17070682-10 2006 DEX acts via GR activation and up-regulation of the expression of the anti-apoptotic protein Bcl-xL. Dexamethasone 0-3 BCL2 like 1 Homo sapiens 93-99 16699951-5 2006 Dex-mediated cytoprotection coincided with the induction of the anti-apoptotic protein, Bcl-X(L). Dexamethasone 0-3 BCL2 like 1 Homo sapiens 88-96 16699951-8 2006 We conclude that Dex-mediated inhibition of apoptosis in C6 glioma cells is through induction of Bcl-X(L). Dexamethasone 17-20 BCL2 like 1 Homo sapiens 97-105 12884026-3 2003 Using cell-culture systems we tested active compounds for their ability to induce apoptosis in Bcl-X(L)-overexpressing MCF7 cells and increase the sensitivities of the cells to apoptosis-inducing drugs [vincristine sulphate, dexamethasone, cycloheximide and 6alpha-methylprednisolone (MP)]. Dexamethasone 225-238 BCL2 like 1 Homo sapiens 95-102 15804364-8 2005 Western blot was used to evidence the effect of dexamethasone on the expression of Cx43, CD95, CIAP2 and BclXL. Dexamethasone 48-61 BCL2 like 1 Homo sapiens 105-110 12393593-6 2002 In contrast, B9 cells overexpressing FGFR3 were resistant to treatment with dexamethasone, a phenomenon successfully reversed using a Bcl-x(L) antisense oligonucleotide. Dexamethasone 76-89 BCL2 like 1 Homo sapiens 134-142 12630918-9 2003 Increased apoptosis after dexamethasone treatment was accompanied by increased immunoreactivity for caspase-3 and decreased immunoreactivity for the anti-apoptotic proteins Bcl-2 and Bcl-x, which further supports our apoptosis results. Dexamethasone 26-39 BCL2 like 1 Homo sapiens 183-188 12637494-3 2003 The anti-apoptotic Bcl-2 family protein Bcl-x(L) is induced by dexamethasone at the transcriptional level at all stages of fibrosarcoma development. Dexamethasone 63-76 BCL2 like 1 Homo sapiens 40-45 12637494-6 2003 Importantly, exogenous Bcl-x(L) inhibits apoptosis and caspase-3 activity in fibrosarcoma cells to levels found in dexamethasone-treated fibrosarcoma cells. Dexamethasone 115-128 BCL2 like 1 Homo sapiens 23-31 10945640-6 2000 Using this culture system of OPM-6, we demonstrated that the treatment with DEX plus a monoclonal antibody to the human IGF-1 receptor (alphaIGF-1R) leads to the down-regulation of the gene expression of Bcl-xL, an antiapoptotic gene, and the activation of CPP32 during this apoptotic process. Dexamethasone 76-79 BCL2 like 1 Homo sapiens 204-210 12381353-13 2002 CD44 cross-linkage up-regulated expression of the pro-apoptotic protein Bax, and down-regulated the anti-apoptotic protein, Bclx(L), in the presence of DEX. Dexamethasone 152-155 BCL2 like 1 Homo sapiens 124-128 11319611-4 2001 Moreover, DEX treatment increased the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins in human and rat hepatocytes, respectively, whereas the expression of pro-apoptotic proteins Bcl-xS or Bad was not detected or remained unchanged. Dexamethasone 10-13 BCL2 like 1 Homo sapiens 77-83 11236942-7 2001 IL-6-induced bcl-XL and cyclin D2 expression in ANBL6 cells, but dexamethasone was able to suppress both bcl-XL and cyclin D2 expression in ANBL6. Dexamethasone 65-78 BCL2 like 1 Homo sapiens 105-111 11085510-2 2000 We report that dexamethasone, but not prolactin, induced native bcl-x gene expression in a dose-dependent manner in HC11 cells and enhanced serum-starved HC11 cell survival. Dexamethasone 15-28 BCL2 like 1 Homo sapiens 64-69 10086739-7 1999 However, IL-6-mediated Bcl-X(L) expression is suppressed in the presence of Dex. Dexamethasone 76-79 BCL2 like 1 Homo sapiens 23-31 10683582-10 2000 Dexamethasone was found to induce a time-dependent up-regulation of Bcl-x(L) protein expression. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 68-76 10547074-7 1999 Dex enhanced the down-regulation of Bcl-X(L) expression in TGF-beta-treated cells, whereas VD3 blocked this down-regulation of Bcl-X(L). Dexamethasone 0-3 BCL2 like 1 Homo sapiens 36-44 9443402-6 1998 BCL-X expression in malignant plasma cells strongly correlated with decreased response rates in patient groups treated with either melphalan and prednisone or vincristine, Adriamycin, and dexamethasone. Dexamethasone 188-201 BCL2 like 1 Homo sapiens 0-5 35205731-7 2022 Mechanistically, dexamethasone induces a pro-apoptotic BCL2-interacting mediator of cell death (BIM) expression and apoptosis in ALL cells but enhances pro-survival B-cell lymphoma extra-large (BCLXL) expression in cardiomyocytes and clinical recovery with the reversion of cardiac atrophy. Dexamethasone 17-30 BCL2 like 1 Homo sapiens 194-199 7669718-0 1995 Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Dexamethasone 95-108 BCL2 like 1 Homo sapiens 21-27 7669718-1 1995 Treatment of M1 myeloid leukemic cells with interleukin 6 (IL-6) or dexamethasone (DEX), both of which induce differentiation in these cells, down-regulated expression of the apoptosis-suppressing gene bcl-2 and the apoptosis-promoting gene bax but up-regulated expression of the apoptosis-suppressing gene bcl-XL. Dexamethasone 68-81 BCL2 like 1 Homo sapiens 307-313 7669718-1 1995 Treatment of M1 myeloid leukemic cells with interleukin 6 (IL-6) or dexamethasone (DEX), both of which induce differentiation in these cells, down-regulated expression of the apoptosis-suppressing gene bcl-2 and the apoptosis-promoting gene bax but up-regulated expression of the apoptosis-suppressing gene bcl-XL. Dexamethasone 83-86 BCL2 like 1 Homo sapiens 307-313 7669718-2 1995 There was a higher expression of bcl-XL in cells treated with DEX or DEX plus IL-6 compared to cells treated with IL-6 alone. Dexamethasone 62-65 BCL2 like 1 Homo sapiens 33-39 7669718-2 1995 There was a higher expression of bcl-XL in cells treated with DEX or DEX plus IL-6 compared to cells treated with IL-6 alone. Dexamethasone 69-72 BCL2 like 1 Homo sapiens 33-39 7669718-5 1995 Withdrawal of DEX after up-regulation of bcl-XL resulted in a decrease in bcl-XL expression and a concomitant increase in cell susceptibility to induction of apoptosis. Dexamethasone 14-17 BCL2 like 1 Homo sapiens 41-47 7669718-5 1995 Withdrawal of DEX after up-regulation of bcl-XL resulted in a decrease in bcl-XL expression and a concomitant increase in cell susceptibility to induction of apoptosis. Dexamethasone 14-17 BCL2 like 1 Homo sapiens 74-80 9326359-0 1997 Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 93-98 9326359-5 1997 Dexamethasone not only suppressed the apoptosis-associated upregulation of Bcl-xS but also enhanced the basal level of Bcl-xL in the cells. Dexamethasone 0-13 BCL2 like 1 Homo sapiens 119-125 9326359-6 1997 In addition, bcl-x mRNA stability was significantly extended in the presence of dexamethasone. Dexamethasone 80-93 BCL2 like 1 Homo sapiens 13-18 9326359-7 1997 These results indicate that dexamethasone exerted a protective effect and delayed apoptosis of TMK-1 cells by modulating bcl-x gene expression. Dexamethasone 28-41 BCL2 like 1 Homo sapiens 121-126